FoidSlayer
we will all ascend
- Joined
- Dec 15, 2025
- Posts
- 9,457
- Reputation
- 27,916
Erdafitinib is a pan fgfr inhibitor that acts on fgfrs 1-4
Erda is potent with IC50 values coming in at
1.2 nM fgfr1
2.5 nM fgfr2
3.0nM fgfr3
5.7nM fgfr4
Now let's get into it, normally in the epiphyseal plate fgfr3 is heavily expressed in the proliferation zone and once they become hypertrophic chondrocytes they predominantly express fgfr1
Fgfr3 activation β FRS2 β GRB2 β SOS β ras β raf β MEK β ERK β Brake on hypertrophic chondrocytes
Fgfr3 activation β PP2a activation β dephosphorylation of p107 β Inhibition of proliferating chondrocytes
Fgfr3 activation β STAT1 β nuclear translocation and activates cell cycle Inhibitor, p21 β inhibition of proliferating chondrocytes
Snail1 is also upregulated in the chondrocyte when fgfr3 is bound and is essential for STAT1 and MAPK signalling
Fgfr1 in the hypertrophic zone also works via similar mechanisms to inhibit how much those cells expand
fgfr2 in the growth plate helps with ossification and is located in the secondary ossification zone and also the perichondrium. Fgfr2 -/- mice had impaired PTHrP and ihh expression. This tells us that abaloparatide should be used if we inhibit fgfr2 heavily
The main fgfs that work on growth plate senescence is fgf 9 and 18
Fgfr3 Inhibition caused the physis in a patients wrist to widen, obviously because of the wider proliferation and hypertrophic zones. It also made another patients bone age stay two years behind his chronological age even post erdafitinib
The effects of erdafitinib are sex steroid independent and even with little signalling if growth factors involved (Ex. Early tanner stages ~2-3) skeletal overgrowth still occured. Probably because the growth factors that did act on his chondrocytes restored the AKT pathway but not the MAPK pathway
Normally fgfr3 downregulated AKT via GRB2 β GAB1 β PI3K β AKT downregulation
Dosing for erdafitinib for height:
Now this had me a little stumped but I figured it out, you must take clearance values, average concentration, converting ng/ml to nM, free fraction, and then running it through hills equation
Reference for 2mg erdafitinib in a healthy human
Cancer dose = 8mg
Cavg cancer patient = 1220ng/ml
Clearance cancer = 0.29
Clearance healthy = 0.43
Free fraction healthy = 0.510%
Desired dose = 2mg
Erdafitinib molecular weight = 447 g/mol
Now let's do this
Cavg healthy = 1,220 β’ 0.29/0.43 β 823ng/ml
823 β’ 2/8 β 206ng/ml
206/447 β’ 1000 = 461nM
461 β’ 0.00510 β 2.35nM
FGFR2 = 2.35/2.35+2.5 β 48% Inhibition
FGFR3 = 2.35/2.35+3.0 β 43% Inhibition
Now that that's wrapped up, let's get theoretical.
Theory (grayx2 walks in)
Fgfr work in osteoblasts and suture mesenchymes in the skull. Now normally fgfr1/2/3 differentiation osteoblasts super quickly and immaturely. This causes alkaline phosphate window to decrease thus impaired hydroxyapatite.
Also immature osteoblasts release their own hydroxyapatite inhibiting signals, which is why we see a lot of fgfr deletion or activation genotypes to have poor mineralization with varying effects on bone mass and BMD
The fgfrs also inhibit bone marrow stem cells thus leaving the progenitor pool exhausted and also having less progenitors while pushing them to differentiate fast is a lot of stress
Hence why deletion genotypes still have poor mineralization, the sheer amount of progenitors just overlaps with each other and causes the system of mineralization to become sloppy.
Now Inhibition of let's say 50% of fgfr2 may help this problem and allow us to make some theoretical craniofacial gains. Now because fgfr2 is expressed in the suture mesenchymes, and taking these mesenchymal cells and differentiating them into osteoblasts super quickly via PKCβ runX2 β osteolineage
This means your sutures will differentiate slower because we are inhibiting this process. Also the more progenitors means more periosteal out growth (the fgfr deletion genotype had higher bone mass despite poorer mineralization )
Now according to implant studies, sutures experience growth after puberty, probably from strong mechanical forces. You see when a suture is histologically fused that's not the same as an implant study. A suture isn't just going to fuse one day you hit this age, it's going to gradually grow tiny bone bridges and eventually fuse completely way later in life.
And when implant studies experience the growth outside of puberty it's those little bone bridges breaking due to mechanical force but they get ossified quickly again by fgfr2
So we are essentially keeping sutures undifferentiated for longer and applying mechanical force via maxillary expansion device and orthodontic head gear to move the maxilla forward
Mechanical forces break the tiny bone bridges, so you could theoretically bonesmash whilst on erdafitinib to allow for other theoretical growth in your zygos, mandible and gonions
Then once we are done with erdafitinib, we are going to wait for the drug to leave our system once we get our head gear and expansion device unscrewed from the roof of our mouth we can then use PTHrP analog to rapidly ossify the spongy material we've created in our skull into bone
@Includings @Mr. Oxytocin fuckin fags
Erda is potent with IC50 values coming in at
1.2 nM fgfr1
2.5 nM fgfr2
3.0nM fgfr3
5.7nM fgfr4
Now let's get into it, normally in the epiphyseal plate fgfr3 is heavily expressed in the proliferation zone and once they become hypertrophic chondrocytes they predominantly express fgfr1
Fgfr3 activation β FRS2 β GRB2 β SOS β ras β raf β MEK β ERK β Brake on hypertrophic chondrocytes
Fgfr3 activation β PP2a activation β dephosphorylation of p107 β Inhibition of proliferating chondrocytes
Fgfr3 activation β STAT1 β nuclear translocation and activates cell cycle Inhibitor, p21 β inhibition of proliferating chondrocytes
Snail1 is also upregulated in the chondrocyte when fgfr3 is bound and is essential for STAT1 and MAPK signalling
Fgfr1 in the hypertrophic zone also works via similar mechanisms to inhibit how much those cells expand
fgfr2 in the growth plate helps with ossification and is located in the secondary ossification zone and also the perichondrium. Fgfr2 -/- mice had impaired PTHrP and ihh expression. This tells us that abaloparatide should be used if we inhibit fgfr2 heavily
The main fgfs that work on growth plate senescence is fgf 9 and 18
Fgfr3 Inhibition caused the physis in a patients wrist to widen, obviously because of the wider proliferation and hypertrophic zones. It also made another patients bone age stay two years behind his chronological age even post erdafitinib
The effects of erdafitinib are sex steroid independent and even with little signalling if growth factors involved (Ex. Early tanner stages ~2-3) skeletal overgrowth still occured. Probably because the growth factors that did act on his chondrocytes restored the AKT pathway but not the MAPK pathway
Normally fgfr3 downregulated AKT via GRB2 β GAB1 β PI3K β AKT downregulation
Dosing for erdafitinib for height:
Now this had me a little stumped but I figured it out, you must take clearance values, average concentration, converting ng/ml to nM, free fraction, and then running it through hills equation
Reference for 2mg erdafitinib in a healthy human
Cancer dose = 8mg
Cavg cancer patient = 1220ng/ml
Clearance cancer = 0.29
Clearance healthy = 0.43
Free fraction healthy = 0.510%
Desired dose = 2mg
Erdafitinib molecular weight = 447 g/mol
Now let's do this
Cavg healthy = 1,220 β’ 0.29/0.43 β 823ng/ml
823 β’ 2/8 β 206ng/ml
206/447 β’ 1000 = 461nM
461 β’ 0.00510 β 2.35nM
FGFR2 = 2.35/2.35+2.5 β 48% Inhibition
FGFR3 = 2.35/2.35+3.0 β 43% Inhibition
Now that that's wrapped up, let's get theoretical.
Theory (grayx2 walks in)
Fgfr work in osteoblasts and suture mesenchymes in the skull. Now normally fgfr1/2/3 differentiation osteoblasts super quickly and immaturely. This causes alkaline phosphate window to decrease thus impaired hydroxyapatite.
Also immature osteoblasts release their own hydroxyapatite inhibiting signals, which is why we see a lot of fgfr deletion or activation genotypes to have poor mineralization with varying effects on bone mass and BMD
The fgfrs also inhibit bone marrow stem cells thus leaving the progenitor pool exhausted and also having less progenitors while pushing them to differentiate fast is a lot of stress
Hence why deletion genotypes still have poor mineralization, the sheer amount of progenitors just overlaps with each other and causes the system of mineralization to become sloppy.
Now Inhibition of let's say 50% of fgfr2 may help this problem and allow us to make some theoretical craniofacial gains. Now because fgfr2 is expressed in the suture mesenchymes, and taking these mesenchymal cells and differentiating them into osteoblasts super quickly via PKCβ runX2 β osteolineage
This means your sutures will differentiate slower because we are inhibiting this process. Also the more progenitors means more periosteal out growth (the fgfr deletion genotype had higher bone mass despite poorer mineralization )
Now according to implant studies, sutures experience growth after puberty, probably from strong mechanical forces. You see when a suture is histologically fused that's not the same as an implant study. A suture isn't just going to fuse one day you hit this age, it's going to gradually grow tiny bone bridges and eventually fuse completely way later in life.
And when implant studies experience the growth outside of puberty it's those little bone bridges breaking due to mechanical force but they get ossified quickly again by fgfr2
So we are essentially keeping sutures undifferentiated for longer and applying mechanical force via maxillary expansion device and orthodontic head gear to move the maxilla forward
Mechanical forces break the tiny bone bridges, so you could theoretically bonesmash whilst on erdafitinib to allow for other theoretical growth in your zygos, mandible and gonions
Then once we are done with erdafitinib, we are going to wait for the drug to leave our system once we get our head gear and expansion device unscrewed from the roof of our mouth we can then use PTHrP analog to rapidly ossify the spongy material we've created in our skull into bone
@Includings @Mr. Oxytocin fuckin fags






